Virax Biolabs Group Ltd (VRAX) Total Liabilities (2021 - 2025)

Virax Biolabs (VRAX) has 5 years of Total Liabilities data on file, last reported at $964750.0 in Q1 2025.

• In Q1 2025, Total Liabilities rose 179.48% year-over-year to $964750.0; the TTM figure through Mar 2025 stood at $964750.0 (up 179.48% YoY), while the FY2025 annual figure was $964750.0, up 179.48% from the prior year.
• Total Liabilities advanced to $964750.0 in Q1 2025, from $345194.0 in the prior quarter.
• Across five years, Total Liabilities topped out at $1.2 million in Q1 2022 and bottomed at $345194.0 in Q1 2024.
• A 5-year average of $867038.8 and a median of $908401.0 in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities slumped 62.0% — and 2025, when it jumped 179.48%.
• Year by year, Total Liabilities stood at $871435.0 in 2021, then soared by 42.92% to $1.2 million in 2022, then slipped by 27.06% to $908401.0 in 2023, then slumped by 62.0% to $345194.0 in 2024, then jumped by 179.48% to $964750.0 in 2025.
• The last three Total Liabilities figures came in at $964750.0 (Q1 2025), $345194.0 (Q1 2024), and $908401.0 (Q1 2023), per Business Quant data.

Peer Comparison